Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Giving low dose tricyclics is not justified by evidence
| The first 150 words of the full text of this article appear below. |
EDITOR
The meta-analysis by Furakawa et al must be considered downright
naughty.1 While masquerading as a contribution to an
academic debate about appropriate antidepressant treatment it
actually does little more than endorse the widely held prejudice in
favour of using low dose tricyclics in depression. Published in a
widely read UK general medical journal, it will inevitably encourage a
practice that is not encouraged by either the Royal College of
Psychiatrists or the American Psychiatric Association.
The subject of optimal dosage of tricyclics remains controversial, but the value of treatment with tricyclic antidepressants at standard dosage compared with placebo is abundantly clear. As Furakawa et al concede but perhaps do not emphasise sufficiently, the evidence for low dose tricyclic antidepressants is of generally poor quality. Many of the trials used in their analysis took place before standardised diagnostic or outcome criteria were commonplace.
What is less clear is the
Read all Rapid Responses